CrowdStrike Faces Investor Unrest as Revenue Misses Mark Despite Profit Hike

Generated by AI AgentAinvest Movers Radar
Wednesday, Jun 4, 2025 6:36 pm ET1min read

CrowdStrike Holdings recently experienced significant stock fluctuations, with a notable drop following the release of its quarterly revenue guidance. The cybersecurity firm anticipates revenues between $1.14 billion and $1.15 billion for the current quarter, which falls short of analysts' expectations of $1.16 billion. Still, adjusted earnings per share are forecasted slightly above expectations, ranging from $0.82 to $0.84, compared to the anticipated $0.81.

The company's outlook continues to be impacted by last year's major outage incident that disrupted operations, including grounding flights and delaying hospital surgeries. To retain customer loyalty,

introduced a "customer commitment package" incentive, which has now ended. CFO Burt Podbere noted this initiative led to a revenue reduction of approximately $11 million this quarter and could further reduce revenue by $10 million to $15 million by the fiscal year's end.

Evercore ISI analyst Peter Levine has downgraded the stock rating due to its high valuation and ongoing unforeseen events, which in his view limit upside potential. Levine cited mounting investor concerns over unresolved issues affecting the company's growth prospects.

Despite the lackluster guidance, CrowdStrike managed to exceed expectations in its first-quarter earnings, with revenues aligning with projections. The adjusted earnings per share of $0.73 surpassed the forecast of $0.65. Although the firm raised its full-year profit outlook, the revenue projection remains unchanged.

Financially, the quarter saw a 20% year-over-year revenue growth, yet it ended with a net loss of $110.2 million (or $0.44 per share), contrasting with a net profit of $42.8 million (or $0.17 per share) from the previous year. In a strategic move, the company announced a $1 billion stock repurchase program.

Comments



Add a public comment...
No comments

No comments yet